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Abstract 
Acetaminophen is the leading cause of acute liver injury in the developed world. Timely 
administration of N-Acetylcysteine (N-Ac) prevents the progression of serious liver 
injury and disease, while failure to administer N-Ac within a critical time frame allows 
disease progression and in the most severe cases may result in liver failure or death. In 
this situation, liver transplantation may be the only life-saving measure. Thus, the 
outcome of an acetaminophen overdose depends upon the size of the overdose and the 
time to first administration of N-Ac. We developed a system of differential equations to 
describe acute liver injury due to acetaminophen overdose. The Model for 
Acetaminophen-induced Liver Damage (MALD) uses a patient's AST, ALT, and INR 
measurements on admission to estimate overdose amount, time elapsed since overdose, 
and outcome. The mathematical model was then tested on 53 patients from the University 
of Utah. With the addition of serum creatinine, eventual death was predicted with 100% 
sensitivity, 91% specificity, 67% PPV, and 100% NPV in this retrospective study. Using 
only initial AST, ALT, and INR measurements, the model accurately predicted 
subsequent laboratory values for the majority of individual patients. This is the first 
dynamical rather than statistical approach to determine poor prognosis in patients with 
life-threatening liver disease due to acetaminophen overdose. Conclusion: MALD 
provides a method to estimate overdose amount, time elapsed since overdose, and 
outcome from patient laboratory values commonly available on admission in cases of 
acute liver failure due to acetaminophen overdose and should be validated in multicentric 
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1  Introduction 
Acetaminophen (APAP: N-acetyl-para-aminophenol) is the leading cause of acute liver 
injury in the USA, accounting for some 56,000 emergency room visits, 26,000 hospital 
admissions and about 500 deaths annually [1]. APAP toxicity is caused by the formation, 
within hepatocytes, of N-acetyl-p-benzoquinoneimine (NAPQI), a highly reactive 
benoquinonamine [2,3]. Intracellular NAPQI initially binds to glutathione (GSH), and is 
safely eliminated [4,5]. Once GSH stores are depleted, residual free NAPQI reacts with 
cellular components and causes injury to APAP-metabolizing hepatocytes [6,7]. Early 
administration of the GSH precursor, N-acetylcysteine (N-Ac), ideally within 12 hours of 
overdose, prevents life-threatening liver injury, and assures recovery [46]. Later 
administration may limit the liver injury, but its utility decreases with time [46,8]. In the 
presence of a sufficiently large overdose, the administration of N-Ac beyond a certain 
time window becomes futile. In these cases, liver transplantation becomes the only life-
saving measure.  
 
A number of factors may determine whether a dose of APAP is fatal. Among the most 
important are the size of the overdose and the time to first administration of N-Ac [46]. 
Unfortunately, these two values are frequently not available at the time of admission to 
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timing or the dose of drug taken, and concomitant use of other medications or drugs often 
obscures the clinical picture.  
 
We therefore sought a method for rapidly determining the time of overdose, extent of 
injury, and likelihood of spontaneous survival using laboratory data available at the time 
of admission.  Our method is based on a mathematical model that describes typical 
hepatic injury progression, dependent only on overdose amount.  Fitting patient lab 
values to our mathematical model allows for the estimation of overdose amount and 
timing, as well as a prediction of outcome.  We tested the mathematical model on 53 
patients from the University of Utah. 
2  Methods 
2.1 Model Background 
Our mathematical model, the Model of Acetaminophen-induced Liver Damage (MALD), 
is based on a reproducible pattern of APAP-induced liver injury. The enzymes aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) are released by injured 
hepatocytes [9,10]. These enzymes peak at about 36 hours from initial injury, and have 
distinct injury and clearance curves. AST concentration in blood is initially 
approximately double that of ALT, with a clearance rate of about 50% every 24 hours. 
ALT peaks at the same time as AST, but with a slower elimination rate of about 33% 
every 24 hours [11]. These measures of damage are complemented by a measure of liver 
function, prothrombin time/international normalized ratio (INR). Decreased production of 
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characteristic rates of increase and decay [12]. The values of AST, ALT, and INR at the 
time of admission thus encode the course of disease progression over time, and can be 
used, with a suitable mathematical model, to estimate initial dose and time of overdose.  
 
2.2  Model description 
We developed a system of nonlinear ordinary differential equations to describe the 
temporal dynamics of APAP-induced ALF based on known mechanisms of 
acetaminophen metabolism (Supplementary Information). The equations describe NAPQI 
production from acetaminophen metabolism, glutathione conjugation, hepatocyte death 
by NAPQI, release and clearance of AST and ALT in the blood, hepatocyte regeneration, 
and clotting factor production (figure 1). The variables and parameters can be divided 
into those describing hepatocyte, acetaminophen, glutathione, INR, and AST/ALT 
dynamics.  
 
Functional hepatocytes (H) become damaged hepatocytes (Z) and regenerate with the 
following parameters:  
• the number of hepatocytes in a healthy liver is Hmax=1.6*1011 [14] 
• damaged hepatocytes lyse with rate δz =5/day 
• functional hepatocytes regenerate with rate r=1/day [15] 
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• the fraction of liver required for survival is µ= 0.3 [16]. 
Serum APAP (A) is a surrogate for liver APAP which is converted to NAPQI (N) with 
the following parameters:  
• APAP is cleared by hepatocytes with rate α = 6.3/day [17] 
• APAP is cleared unconjugated with rate δa = 0.33/day [2,3] 
• the fraction of APAP that is oxidized to NAPQI is p=0.05 [2,3] 
• the conversion factor from grams of APAP to mol of NAPQI is q=0.0067 mol/g. 
GSH (G) is associated with the following parameters:  
• GSH binds to NAPQI with rate γ = 1.6*1018 cell/mol/day [18] 
• GSH decays with rate δg =2/day [19] [20] [21] 
• GSH is produced with rate κ  = 1.375*10-14 mol/cell/day. 
INR (I) is related to the clotting factor concentration as a fraction of normal (F) and is 
associated with the following parameters:  
• clotting factor VII is cleared with rate βf =5/day [22] 
• the minimum clotting factor concentration is Fmin=0.75. 
Serum AST concentration (S) and serum ALT concentration (L) increase and decay with 
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• AST is cleared with rate δs=0.92/day [11] 
• ALT is cleared with rate δ l =0.35/day [11] 
• the total amount of AST in a healthy liver is βs =200,000 IU 
• the total amount of ALT in a healthy liver is βl =84,800 IU 
• the amount of blood in a human body is θ  = 5 L 
• the minimum AST level is Smin=12 IU/L 
• the minimum ALT level is Lmin=9 IU/L. 
Six parameters were adjusted to match properties of the data, independent of patient 
survival information. The amounts of AST and ALT in the liver, βs  and βl , respectively, 
were scaled to the maximum observed AST and ALT values, and the minimum AST and 
ALT levels, Smin and Lmin, respectively, were scaled to the minimum observed AST and 
ALT values. The minimum clotting factor concentration Fmin was scaled to the maximum 
observed INR value. The damaged hepatocyte lysis rate δz  was adjusted to the timing of 
peak AST and ALT values.  
 
Two parameters were scaled to the dose of APAP required for hepatotoxicity and death. 
The glutathione production rate, κ , was scaled to the dosage at which glutathione 
reserves are depleted. The minimum dosage predicted to lead to hepatotoxicity varies, but 
typically ranges from 7.5 to 10 gm for an adult [8,23]. We chose a slightly lower value of 
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hepatocytes become damaged by NAPQI, η, is a scaling factor that was chosen so that a 
20 gram overdose is equivalent to 70% hepatic necrosis and predicted death.  
2.3  Patients 
Between January 1, 2006 and December 31, 2009 all hospital discharges from the 
University of Utah were queried for the diagnosis of severe, acute APAP toxicity. Charts 
were excluded if they included acute hepatitis A or B, autoimmune hepatitis, Wilson 
disease, or multisystem failure. Laboratory data, and admission and discharge notes were 
further reviewed to identify cases in which acute liver disease was due to APAP overdose 
only. Charts that had overdose with additional medications were not included in this 
analysis. Demographics, N-Ac administration, and medical outcome information were 
collected. Laboratory results of AST, ALT, INR, bilirubin, and creatinine were also 
collected. Charts without at least one measure of AST, ALT, and INR were excluded 
from the study. In total, 53 patients were included. The patient population was diverse, 
with varying alcohol use, body mass index, and ingestion type, including suicide 
attempts, single accidental overdoses, and multiple day chronic overdoses.  
2.3.1  Ethics statement 
Patient consent was not obtained since data were retrospective, were based on standard 
care, and were analyzed anonymously. The protocol was approved by the IRB of the 
University of Utah in accordance with the Declaration of Helsinki.  
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Serum creatinine was added as an additional criterion separate from the model since it is 
a marker of kidney damage, and our dynamic model does not describe kidney damage. 
Since kidney function is ultimately important in survival in APAP overdose, patients with 
serum creatinine greater than 3.4 mg/dL were predicted to die [24].  
2.5  Fitting the model to individual patients 
Upon admission, before administration of N-Ac, a patient's AST, ALT, and INR values in 
the mathematical model are a function of two parameters, APAP overdose amount, A0, 
and time since overdose, τ . These two parameters were estimated using weighted least 
squares and values of AST, ALT, and INR on admission. The weights were determined 
by post-treatment model fits (see Supplementary Information for more detail). To test the 
sensitivity of predicted outcomes to changes in parameters, we increased and decreased 
each parameter by 50% of its original value and fit individuals to the model, keeping 
track of the predicted outcome for each patient.  
3  Results 
We tested the model on 53 patients from the University of Utah. The time since overdose 
and overdose amount were estimated for each patient using initial measurements of AST, 
ALT, and INR on admission (figure 2). Based on the extent of estimated liver injury, the 
model predicts death for patients who took over 20 grams of APAP without N-Ac 
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Excluding patients who were transplanted, death versus recovery can be predicted with 
75% sensitivity and 95% specificity (table 1). With the addition of initial serum 
creatinine exceeding 3.4 mg/dL, sensitivity increased to 100%. For this data set, the 
subset of the King's College Criteria (KCC) to which we had access (INR > 6.5 and 
creatinine > 3.4 mg/dL) had 13% sensitivity and 100% specificity. Only one patient had 
both INR > 6.5 and creatinine > 3.4 on admission. Thinking of the KCC as either INR > 
6.5 or creatinine > 3.4 mg/dL increases sensitivity to 88%. We did not have access to 
patient encephalopathy or arterial pH.  
 
Using only data available on admission, the model results fit the post-treatment time-
series of the markers of liver damage for the majority of individual patients 
(Supplementary Information table 2). The results from four representative patients are 
shown in figure 3. Patients 5 and 8 were predicted to have had overdoses that were very 
close to the lethal threshold, whereas patient 49 was predicted to have exceeded the lethal 
threshold. Patient 16 was predicted to have had a smaller overdose. The confidence 
region for some patients who recovered (e.g. patient 16) includes regions with high 
overdose amount and very early N-Ac administration, as well as regions with low 
overdose amount and late N-Ac administration. In both cases AST, ALT, and INR are 
low.  
 
Model predictions of outcome were robust to 50% increase or decrease in parameter 
values (Supplementary Information table 3). The most sensitive model parameters were 
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Increasing µ  to 0.45 caused more patients who eventually recovered to be predicted to 
die, and resulted in 100% sensitivity and 77% specificity, while decreasing µ  to 0.15 
resulted in 88% sensitivity and 93% specificity. Increasing βs  by 50% resulted in 100% 
sensitivity and 79% specificity, while decreasing βs  by 50% resulted in 88% sensitivity 
and 88% specificity.  
 
Some parameters such as p, the fraction of APAP oxidized to NAPQI, have a large effect 
on predicted dose of APAP, but no effect on predicted outcome. If p is 0.025, an 
overdose amount of 40 grams is required for 70% hepatic necrosis and predicted death, 
while if p is 0.075, an overdose amount of 13.3 grams is required for 70% hepatic 
necrosis and predicted death.  Estimates of overdose amount scale with lethal dose so that 
estimates of outcome remain the same despite large changes in estimated overdose 
amount.  
 
4  Discussion 
APAP, alone or in combination, accounts for about 50% of cases of ALF in the USA 
[25]. Survival largely depends on two parameters: the size of the initial dose and time 
elapsed prior to the administration of N-Ac. Very early administration (up to 12 hours 
after overdose) of N-Ac results in almost 100% survival [46].  
 
Some models of APAP toxicity rely on the time between ingestion and hospital 
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These are risky approaches because the timing of the overdose provided by the patient is 
frequently unobtainable or unreliable. Moreover, patients who arrive at the hospital 24 
hours or more post-ingestion may have plasma acetaminophen levels below the detection 
limit.  
 
The King's College Criteria (KCC) [24] provide a well-validated method for predicting 
death without transplantation in APAP-induced ALF [37], although they have been 
criticized for low sensitivity [38] and low negative predictive value [39]. KCC used an 
initial data set of 310 patients to identify statistically significant prognostic indicators to 
distinguish survivors and nonsurvivors and used a validation set of 121 patients to 
identify cutoff values associated with survival rates less than 20% for the statistically 
significant prognostic indicators, with no physiologically defined model of mortality. 
Many modifications of the KCC have been suggested [e.g. 40-45], perhaps most 
importantly the addition of arterial lactate [47].  Arterial lactate has consistently been 
shown to be associated with survival, although its prognostic value has been questioned 
[48].   
 
In contrast to other modifications of the KCC, MALD is novel because we build upon the 
KCC by utilizing an understanding of the dynamics of hepatocyte damage following 
APAP overdose in the form of a dynamic mathematical model. Hepatic necrosis is 
directly related to the extent of covalent binding of NAPQI to intracellular components 
[6,7,4,2], which causes hepatocyte lysis and release of AST and ALT into the blood. This 
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AST, ALT, and INR.  We have developed a system of differential equations based on the 
principles of APAP-induced liver damage. All parameters in MALD were estimated from 
the literature, except six that were adjusted to match general properties of AST and ALT 
dynamics, and two that were scaled to the dosages thought to cause hepatotoxicity and 
death. Survival information from University of Utah patients was not used in model 
development or parameterization. The equations describe how AST, ALT, and INR levels 
change over time as a function of overdose amount.  Since these curves over time are 
only a function of initial overdose amount, AST, ALT, and INR levels in the model only 
depend on initial overdose amount and time since overdose.  Our method works by fitting 
measured AST, ALT, and INR values to the curves described by our differential 
equations to estimate overdose timing and amount (figure 4). An outcome of death is 
predicted when the estimate of overdose amount is sufficiently high and the estimate of 
timing predicts N-Ac to be ineffectual, or when serum creatinine measurements are 
sufficiently high. If the outcome is predicted to be poor, liver transplantation may be the 
only life-saving treatment.  
 
Previous studies have not found absolute aminotransferase levels to be significant 
predictors of outcome in cases of APAP-induced ALF (e.g. [24]). This is not surprising 
because aminotransferase levels will be low, even with a high dose, both early and late in 
the course of the injury based on known mechanisms of liver damage following APAP 
overdose.  Similarly, high aminotransferase levels may be measured near peak liver 
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mathematical model describing these mechanisms, however, aminotransferase levels do 
contain sufficient information to estimate the timing and amount of overdose.  
 
Our model cannot distinguish patients with high overdose amounts and early 
administration of N-Ac from patients with low overdose amounts and delayed treatment 
because in both cases AST, ALT, and INR levels are low. However, this ambiguity 
affects only patients who are predicted to recover.  
 
Some patients with unique characteristics, such as those with significant muscle damage, 
may not fit the model. Muscle damage increases the level of AST, which may lead to 
poor estimation of liver damage. Since ALT and INR values are not affected by muscle 
damage, this effect may be minimal. Further studies are warranted to determine whether 
more refinements are needed for special patient groups. 
 
Our treatment of all patients as having the same parameter values is unrealistic. Well-
known covariates of disease severity such as age [27], chronic alcohol use [28,29], 
starvation or malnutrition [30], and interactions with other drugs [31,32,33] may affect 
the parameter values of an individual. In some cases these differences will not affect the 
accuracy of predictions of outcome. Model predictions derive from the amount of 
unconjugated NAPQI that results from a given dose, but that amount may depend on 
patient characteristics. For example, alcoholics may make excessive NAPQI because of 
elevated p-450 levels, or individuals may have decreased levels of GSH because of 
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make the model estimates of initial dose seem overly high, but the outcome could still be 
accurately predicted because these patients have more unconjugated NAPQI than is 
typical for the overdose amount.  
 
James et al. [34] show that acetaminophen protein adduct levels may be used as specific 
biomarkers of APAP toxicity. If measurements were routinely available, adducts could 
easily be added to our model, and might provide additional predictive value. However, 
the correlation of protein adducts with AST and their similar kinetics lead us to predict 
this effect would be small, although their more direct relationship to liver damage might 
reduce noise and make them a superior predictor.  
 
Gregory et al. [35] found that individuals with overdose amounts greater than 10 grams 
did not have significantly different mortality than those reporting smaller overdoses in 
patients with eventual hepatic encephalopathy. The authors suggest that this may be due 
to inaccurate reporting of dosing information by patients with eventual hepatic 
encephalopathy, or from a plateau effect in APAP overdose amount, such that above a 
threshold, the effect of APAP overdose ceases to be additive. A plateau is built into our 
model, but at 20 grams rather than 10 grams. In our model, without treatment, any 
overdose above 20 grams will result in severe hepatic injury resulting in maximal AST, 
ALT, and INR levels and poor outcome. Our patient set is quite different since Gregory et 
al. required eventual hepatic encephalopathy for inclusion, a parameter unknown on 
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Methods to determine whether to use dangerous and costly interventions, such as 
transplantation, will ideally be based on clinical data that are readily available at the time 
of admission.  Using only initial measurements of AST, ALT and INR, we were able to 
predict the hepatic injury progression and extent of liver damage following APAP 
overdose. Unlike statistical models to predict outcome, which must build upon 
survivorship data, our mechanistic approach is based on the independently testable 
assumption that 70% hepatic necrosis leads to death.  Our dynamic model yields a 
prediction of outcome by estimating the time since overdose and overdose amount from 
commonly obtained laboratory data on admission.  With the inclusion of creatinine, we 
were able, in this retrospective analysis, to predict survival vs. death with 91% 
specificity, 100% sensitivity, 67% PPV, and 100% NPV. Our initial analysis suggests 
that MALD compares favorably to statistical methods, and should be validated in 
multicentric retrospective and prospective evaluation.  
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6  Supplementary Information 
6.1  Model equations 
The dynamics of total serum APAP (A), intracellular NAPQI concentration (N), 
intracellular GSH concentration (G), number of functional hepatocytes (H), number of 
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and serum clotting factor concentration (F) are governed by the following system of 



























Damaged Hepatocytes  
dZ
dt








= dzβlθHmax Z −δ l L − Lmin( )
Clotting Factor  
dF
dt








APAP is cleared by conjugation at rate α H
Hmax
, and a small amount is cleared 
unconjugated at rate δa . A fraction p of the APAP is converted to NAPQI and is cleared 
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logistically with rate r saturating at Hmax and become damaged at rate ηN  releasing AST 
and ALT into the blood at rates 
dzβs
θHmax  and 
dzβl
θHmax , respectively. Clotting factors are 
produced by hepatocytes and decay at a rate βf . INR (I) is related to the concentration of 










6.2  Post-treatment model fits 
To estimate uncertainty in measurements of AST, ALT, and INR, we define a post-
treatment model as a special case of the pre-treatment model. Treatment with N-Ac leads 
to a high concentration of intracellular GSH, preventing further damage to hepatocytes 




= −δzZ  
dS
dt
= dzβsθHmax Z −δ s S − Smin( ), 
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= −δzZ  
dL
dt
= dzβlθHmax Z −δ l L − Lmin( ), 
 




= −δzZ  
dH
dt
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The post-treatment model subsystems were fit to individual patients using least squares. 
In the AST subsystem, the modeled AST value is a function of two parameters, the 
modeled AST concentration at the time of admission, S0, and the number of damaged 
hepatocytes on admission, Z0. For each individual patient, the best fit solution is the one 
that minimizes, over all possible combinations of S0 and Z0, the sum of the squared 
residual  
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 where ASTi is the patient's measured AST value i days after the first measurement, and 
Si(S0,Z0) is the modeled AST value i days after the first measurement with initial 
conditions S0 and Z0. All logarithms indicate the natural log. The residual for each 
measurement is defined as log(ASTi)-log(Si(S*0,Z*0)) where S*0 and Z*0 are the AST and 
damaged hepatocyte initial conditions that minimize the least squares problem, 
respectively. The standard deviation of all of the residuals from all measurements of AST 
from all patients is ω s=0.60.  
 
Using the same approach described above, but replacing ASTi, Si, and S0 by ALTi, Li, and 
L0, respectively, the standard deviation of all of the residuals from all measurements of 
ALT from all patients is ω l =0.43.  
 
For INR, the modeled value Ii depends on three parameters, modeled clotting factor 
concentration at the time of admission, F0, modeled number of damaged hepatocytes at 
admission, Z0, and modeled number of functional hepatocytes at admission, H0. Again 
minimizing the least squares difference between measured INRi and modeled Ii(F0, Z0, 
H0), the standard deviation of the residuals from all measurements of all patients is 
ω i=0.26.  
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For each patient, the estimated overdose amount A0 and τ  are those that minimize  



















where AST, ALT, and INR are a patient's measured AST, ALT, and INR on admission, 
and S, L, and I are modeled AST, ALT, and INR for overdose amount A0 at time τ  since 
overdose.  
 
The confidence regions of A0 and τ  for individual patients in figure 3 are defined as 
follows. We begin with the best least squares estimate for A0 and τ , where the residual R 
takes its minimum R*. We then find regions A0 and τ  for which R is within 0.5 of R*, R 
exceeds R* by 0.5 to 1, R exceeds R* by 1 to 1.5, and R exceeds R* by 1.5 to 2.  
 
The line separating predicted recovery and predicted death in figure 2 was determined by 
numerically solving the full pre-treatment model for a range of A0, marking the time since 
overdose when H equals 30% of its initial value (i.e. 70% hepatic necrosis occurs). The 
estimated probability of death for each patient is calculated as the fraction of R within 2 
of R* for which A0 and τ  lie in the region of predicted death.  
 
To test the sensitivity of model predictions to parameters, we fit patients to the pre-
treatment model with each parameter perturbed by 50% and 150% of its original value. A 
summary of how each parameter perturbation affects sensitivity, specificity, PPV, and 
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7  Table and Figure Legends 
Table 1: Sensitivity, specificity, PPV, and NPV for a subset of King's College Criteria 
(INR > 6.5 and creatinine > 3.4 mg/dL), either INR > 6.5 or creatinine > 3.4 mg/dL, and 
the current study both with and without creatinine as an independent marker. Absolute 
numbers and 95% Clopper-Pearson confidence interval are given in parentheses.  
 
Table 2 (Supplementary Information): Observed AST, ALT, INR, creatinine, and result, 
and predicted overdose amount A0, time since overdose τ , predicted result without 
creatinine, residual, and estimated probability of death. Patients with predicted results 
marked with a star (*) were predicted to die with the inclusion of creatinine.  
 
Table 3 (Supplementary Information): A summary of how changes in parameter values 
affect predictions of outcome.  
 
Figure 1: A schematic diagram representing the dynamics of the mathematical model. A 
fraction of APAP is oxidized to NAPQI, bound to GSH, and safely eliminated. As GSH 
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Meanwhile, functional hepatocytes regenerate and produce essential clotting factors. Red 
represents the intracellular variables, yellow represents healthy and damaged hepatocytes, 
and blue represents markers of liver damage.  
 
Figure 2: MALD derived estimates of time since overdose and overdose amount for 53 
patients with known APAP overdose. Red squares indicate eventual death, green circles 
recovery, and orange triangles transplant. Small white dots indicate INR > 6.5 and small 
black dots indicate serum creatinine > 3.4 mg/dL on admission. The grey line indicates 
overdose amounts and times since overdose for which 70% hepatic necrosis is predicted. 
Patients to the right and above the grey line are predicted to die.  
 
Figure 3: Markers of liver damage (small black open circles) and model predictions (red 
dashed line) based on least squares fits of initial AST, ALT, and INR (large black filled 
circle) to modeled AST, ALT, and INR (large red filled circle) for four representative 
patients. Time t=0 indicates the time of admission to hospital. The estimated overdose 
amount and time since overdose for each patient is given by the orange dot in the lower 
right panel. Refer to the Supplementary Information for more detail.  
 
 
Figure 4: A schematic description of how MALD can be used to estimate overdose 
amount, timing and outcome. Patient AST, ALT, and INR are fit to a family of curves 
described by MALD to estimate overdose amount, timing, and outcome. If outcome is 
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 Model  Specificity  Sensitivity  PPV  NPV 
     
INR > 6.5 and creatinine > 3.4 mg/dL  1 (43/43, 0.92-1)  0.13 (1/8, 0-0.53)  1 (1/1, 0-1)  0.86 (43/50, 0.73-0.94) 
INR > 6.5 or creatinine > 3.4 mg/dL  0.95 (41/43, 0.84-0.99)  0.88 (7/8, 0.47-1)  0.78 (7/9, 0.4-0.97)  0.98 (41/42, 0.87-1) 
MALD (No Creatinine)  0.95 (41/43, 0.84-0.99)  0.75 (6/8, 0.35-0.97)  0.75 (6/8, 0.35-0.97)  0.95 (41/43, 0.84-0.99) 
MALD (With Creatinine)  0.91 (39/43, 0.78-0.97)  1 (8/8, 0.63-1)  0.67 (8/12, 0.35-0.90)  1 (39/39, 0.91-1) 
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patient number  
 





residual  probability 
of death 
           
1 18 27 1.2 0.8 recovery  6.1 3.9 recovery  0.5 0  
3 138 128 1.2 0.5 recovery  6.6 1.9 recovery  0.46 0  
4 6023 3352 11 1.5 transplant  25.1 4.4 death  3.73 1  
5 6432 6390 3 3 recovery  18.9 3.2 recovery  0.23 0.12  
6 5267 12202 4.3 0.6 recovery  20.5 3.4 death  0.82 0.44  
8 11842 6731 3.9 2.6 recovery  16.3 1.6 recovery  0.46 0.15  
9 2381 4960 1.6 0.8 recovery  18.5 4.2 recovery  0.03 0.16  
10 26 19 1.1 0.7 recovery  5.8 1.4 recovery  0.13 0  
11 1546 3642 1.4 0.7 recovery  17.9 4.6 recovery  0.26 0.18  
14 313 402 1.1 0.6 recovery  7.6 2.5 recovery  0.09 0  
16 1427 1497 1.2 0.8 recovery  9.6 2.2 recovery  0.1 0  
17 29 18 1.1 0.6 recovery  5.8 0.8 recovery  0.13 0  
18 17 11 1.3 0.4 recovery  7.1 0.2 recovery  1.04 0  
21 14230 6746 10.5 2.7 death  22.2 2.9 death  1.36 0.99  
22 52 21 1 0.6 recovery  8.1 0.2 recovery  0.11 0  
25 184 48 1 0.7 recovery  17.3 0.1 recovery  0.58 0  
26 15953 5598 2 2.8 recovery  40 0.4 recovery  0.46 0  
28 28 17 1.1 0.8 recovery  5.8 0.7 recovery  0.13 0  
29 10394 8392 3.7 5 death  17.5 2.4 recovery*  0.02 0.14  
31 24 16 1.1 0.6 recovery  5.7 1 recovery  0.14 0  
33 774 443 1.7 0.7 recovery  7.3 0.8 recovery  3.44 0  
36 509 7686 3.3 4 death  25.1 6 death*  2.84 1  
37 53 19 1.1 0.5 recovery  9.9 0.1 recovery  0.39 0  
38 69 71 1 1 recovery  6.3 2.2 recovery  0 0  
39 8122 8134 3.8 0.8 recovery  19 2.9 recovery  0.03 0.17  
41 443 3368 1.9 0.8 recovery  24.7 6.6 death  0.01 1  
43 23 22 1.2 0.7 recovery  5.9 2.3 recovery  0.5 0  
44 35 19 1.2 0.7 recovery  6 0.4 recovery  0.5 0  
47 23 21 1.2 0.6 recovery  5.9 2.1 recovery  0.5 0  
49 7454 5507 17.8 1.4 death  25.7 3.9 death  1.19 1  
51 37 27 1.4 0.9 recovery  5.9 1.4 recovery  1.69 0  
53 626 563 1.6 0.7 recovery  7.7 1.7 recovery  2.75 0  
54 24000 15000 3.1 0.9 recovery  17 1.2 recovery  2.84 0.14  
55 289 1884 1.1 0.6 recovery  15.1 5.9 recovery  0.07 0.31  
58 21 35 1.2 0.7 recovery  6.2 3.9 recovery  0.5 0  
59 5238 3641 17.3 2.8 death  26.4 4.5 death  2.65 1  
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60 6298 2792 21.1 3.8 death  27.1 4.5 death*  5.3 1  
61 230 921 1.7 6.7 transplant  10.5 4.7 recovery*  4.03 0.29  
62 744 903 1.5 0.9 recovery  8.6 2.3 recovery  1.89 0  
63 8029 6989 2 1 recovery  14.6 2.2 recovery  0.1 0  
65 147 117 1.3 0.6 recovery  6.5 1.6 recovery  0.97 0  
67 21 9 1.2 1 recovery  13.9 0.1 recovery  0.86 0  
68 1621 1404 1.8 5.5 recovery  8.9 1.3 recovery*  3.11 0  
71 10810 9218 4.4 2.4 recovery  18.4 2.5 recovery  0 0.23  
74 5562 4449 2.2 3.5 death  13.1 1.7 recovery*  0.76 0.05  
75 14520 9159 2.3 1.3 recovery  14.4 1.6 recovery  0.85 0.02  
77 1545 1228 6.3 1.2 death  26.7 6.3 death  8.26 1  
78 7716 5588 2.3 0.7 recovery  13.9 1.8 recovery  0.15 0  
79 37 13 1.2 0.8 recovery  15.9 0.1 recovery  0.92 0  
81 31 25 1.1 0.7 recovery  5.9 1.7 recovery  0.13 0  
82 115 163 1.5 3.1 recovery  6.9 2.7 recovery  2.41 0  
83 78 52 1.5 0.7 recovery  6.1 1.2 recovery  2.43 0  
84 17161 12147 4.2 3.5 recovery  17.5 1.5 recovery*  0.42 0.23 
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Modified Parameter  New Value Specificity  Sensitivity PPV  NPV 
      
Current Study (With Creatinine)  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
µ  0.45  0.77 (33/43)  1 (8/8)  
0.44 
(8/18)  1 (33/33) 
µ  0.15  0.93 (40/43)  0.88 (7/8)  0.7 (7/10)  
0.98 
(40/41) 
Hmax  2.4*1011  
0.93 
(40/43)  1 (8/8)  
0.73 
(8/11)  1 (40/40) 
Hmax  8*1010  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
βf  7.5  
0.88 





βf  2.5  
0.88 
(38/43)  1 (8/8)  
0.62 
(8/13)  1 (38/38) 
η  480  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
η  160  0.93 (40/43)  1 (8/8)  
0.73 
(8/11)  1 (40/40) 
βl  127200  
0.88 





βl  42400  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
βs  3*105  
0.79 
(34/43)  1 (8/8)  
0.47 
(8/17)  1 (34/34) 
βs  1*105  
0.88 





q  0.01005  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
q  0.00335  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
δl  0.525  
0.88 
(38/43)  1 (8/8)  
0.62 
(8/13)  1 (38/38) 
δl  0.175  
0.93 
(40/43)  0.88 (7/8)  0.7 (7/10)  
0.98 
(40/41) 
δs  1.38  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
δs  0.46  
0.74 





r  1.5  0.84 (36/43)  1 (8/8)  
0.53 
(8/15)  1 (36/36) 
r  0.5  0.93 (40/43)  1 (8/8)  
0.73 
(8/11)  1 (40/40) 
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κ  0.0011  0.93 (40/43)  0.88 (7/8)  0.7 (7/10)  
0.98 
(40/41) 
δg  3  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
δg  1  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
δz  7.5  
0.93 
(40/43)  1 (8/8)  
0.73 
(8/11)  1 (40/40) 
δz  2.5  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
γ  1.5*107  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
γ  5*106  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
p  0.075  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
p  0.025  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
δa  0.495  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
δa  0.165  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
α  9.45  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
α  3.15  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
Fmin  0.85  
0.91 
(39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
Fmin  0.65  
0.93 
(40/43)  1 (8/8)  
0.73 
(8/11)  1 (40/40) 





θ  7.5  0.91 (39/43)  1 (8/8)  
0.67 
(8/12)  1 (39/39) 
Table 3 (Supplemental Information) 






Figure 1: A schematic diagram representing the dynamics of the mathematical model. A fraction of 
APAP is oxidized to NAPQI, bound to GSH, and safely eliminated. As GSH stores are depleted, 
NAPQI damages hepatocytes, releasing AST and ALT into the blood. Meanwhile, functional 
hepatocytes regenerate and produce essential clotting factors. Red represents the intracellular 
variables, yellow represents healthy and damaged hepatocytes, and blue represents markers of liver 
damage.  
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Figure 2: MALD derived estimates of time since overdose and overdose amount for 53 patients with 
known APAP overdose. Red squares indicate eventual death, green circles recovery, and orange 
triangles transplant. Small white dots indicate INR > 6.5 and small black dots indicate serum 
creatinine > 3.4 mg/dL on admission. The grey line indicates overdose amounts and times since 
overdose for which 70% hepatic necrosis is predicted. Patients to the right and above the grey line 
are predicted to die.  
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Figure 3A: Markers of liver damage (small black open circles) and model predictions (red dashed 
line) based on least squares fits of initial AST, ALT, and INR (large black filled circle) to modeled 
AST, ALT, and INR (large red filled circle) for four representative patients. Time t=0 indicates the 
time of admission to hospital. The estimated overdose amount and time since overdose for each 
patient is given by the orange dot in the lower right panel. Refer to the Supplementary Information 
for more detail.  
44x38mm (600 x 600 DPI)  
 
 






Figure 3B: Markers of liver damage (small black open circles) and model predictions (red dashed 
line) based on least squares fits of initial AST, ALT, and INR (large black filled circle) to modeled 
AST, ALT, and INR (large red filled circle) for four representative patients. Time t=0 indicates the 
time of admission to hospital. The estimated overdose amount and time since overdose for each 
patient is given by the orange dot in the lower right panel. Refer to the Supplementary Information 
for more detail.  
46x40mm (600 x 600 DPI)  
 
 






Figure 3C: Markers of liver damage (small black open circles) and model predictions (red dashed 
line) based on least squares fits of initial AST, ALT, and INR (large black filled circle) to modeled 
AST, ALT, and INR (large red filled circle) for four representative patients. Time t=0 indicates the 
time of admission to hospital. The estimated overdose amount and time since overdose for each 
patient is given by the orange dot in the lower right panel. Refer to the Supplementary Information 
for more detail.  
46x40mm (600 x 600 DPI)  
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Figure 4: A schematic description of how MALD can be used to estimate overdose amount, timing 
and outcome. Patient AST, ALT, and INR are fit to a family of curves described by MALD to estimate 
overdose amount, timing, and outcome. If outcome is predicted to be poor, liver transplantation 
may be necessary.  
43x33mm (600 x 600 DPI)  
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